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Background-—Exposure of vascular smooth muscle cells (VSMCs) to excessive cyclic stretch such as in hypertension causes a
shift in their phenotype. The focal adhesion protein zyxin can transduce such biomechanical stimuli to the nucleus of both
endothelial cells and VSMCs, albeit with different thresholds and kinetics. However, there is no distinct vascular phenotype in
young zyxin-deﬁcient mice, possibly due to functional redundancy among other gene products belonging to the zyxin family.
Analyzing zyxin function in VSMCs at the cellular level might thus offer a better mechanistic insight. We aimed to characterize
zyxin-dependent changes in gene expression in VSMCs exposed to biomechanical stretch and deﬁne the functional role of zyxin in
controlling the resultant VSMC phenotype.
Methods and Results-—DNA microarray analysis was used to identify genes and pathways that were zyxin regulated in static and
stretched human umbilical artery–derived and mouse aortic VSMCs. Zyxin-null VSMCs showed a remarkable shift to a growth-
promoting, less apoptotic, promigratory and poorly contractile phenotype with 90% of the stretch-responsive genes being zyxin
dependent. Interestingly, zyxin-null cells already seemed primed for such a synthetic phenotype, with mechanical stretch further
accentuating it. This could be accounted for by higher RhoA activity and myocardin-related transcription factor-A mainly localized
to the nucleus of zyxin-null VSMCs, and a condensed and localized accumulation of F-actin upon stretch.
Conclusions-—At the cellular level, zyxin is a key regulator of stretch-induced gene expression. Loss of zyxin drives VSMCs toward
a synthetic phenotype, a process further consolidated by exaggerated stretch. ( J Am Heart Assoc. 2015;4:e001712 10.1161/
JAHA.114.001712)
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C hronic hypertension is an important risk factor foradverse cardiovascular events, causing a high degree of
morbidity and mortality worldwide.1Consequently, circumfer-
ential wall stress in the arterial wall is increased, triggering a
remodeling process with profound changes in gene expres-
sion of resident cells. This essentially stretch-induced remod-
eling process is driven by a phenotypic shift, namely, of the
vascular smooth muscle cells (VSMCs), which is partly
controlled by transcription factors such as activator protein
1 and serum response factor (SRF).2,3 However, these
transcription factors are also activated by a variety of other
stimuli such as proinﬂammatory cytokines. Recently, the focal
adhesion protein zyxin has been shown to be speciﬁcally
involved in mechanotransduction in endothelial cells and
VSMCs.4–6 Considering the multiplicity of genes and impor-
tant pathways associated with zyxin in our previous studies,4,5
lack of a distinct vascular phenotype in zyxin-deﬁcient mice
was surprising. Functional redundancy among closely related
zyxin family members, namely, lipoma preferred partner (LPP)
and thyroid hormone receptor interactor 6, could mask the
effects of a loss of zyxin in the whole organism. Therefore,
analysis of zyxin function at the cellular level in VSMCs might
offer a better understanding of its role therein.
Zyxin is a structural protein that regulates actin polymeriza-
tion at focal adhesions and stressﬁbers.7,8 It has been implicated
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in regulation of cell adhesion and cell cycle control, with
conﬂicting reports about its role in cell migration.9 Such
processes are crucially involved in adaptive and maladaptive
remodeling of blood vessels. Such remodeling processes
typically involve an initial increase in VSMC migration and
proliferation.10 As opposed to the normally quiescent and
contractile phenotype, VSMCs in remodeling arterial blood
vessels acquire a synthetic phenotype with altered synthesis of
extracellularmatrix components.11 In VSMCs, SRF controls gene
expression, which drives a contractile or a synthetic phenotype,
depending on the transcriptional coactivators that bind to it.12
Among these coactivators are members of the myocardin-
related transcription factor (MRTF) family, namely, myocardin,
MRTF-A and B. While myocardin binds to SRF and drives the
expression of contractile proteins responsible for the differen-
tiated state of VSMCs,13,14 recent evidence suggests that MRTF-
A and B promote synthetic gene expression, particularly under
conditions of reduced myocardin expression as observed in
different models of maladaptive vascular remodeling.15
Exaggerated stretch or increased wall tension such as in
hypertension causes an expulsion of myocardin from the
nucleus to the cytoplasm,16 resulting in reduced myocardin-
dependent SRF activity. Thus, SRF activity can be ﬁne-tuned by
changes in the relative amounts of myocardin and MRTF-A
bound to SRF. Actin polymerization dynamics is a critical
regulator of SRF signaling through promoting the nuclear
localization of MRTF-A.17 Actin polymerization in turn is
regulated by the Rho family GTPase RhoA among other
mechanisms.18 As zyxin is known to play a role in actin
remodeling and its expression is regulated by SRF,19 we
investigated whether genetic zyxin deﬁciency affects SRF
signaling in VSMCs and thus determines their phenotype.
Consequently, we analyzed the role of zyxin in VSMC phenotype
control in vitro through (1) gene expression and pathway
analyses of static (unstretched) and stretched VSMCs from
wild-type and zyxin-deﬁcient mice, and (2) phenotypically
characterizing these cells to gain an insight into the underlying
mechanism likely involving the MRTF–SRF axis.
Methods
Cell Culture
Mouse VSMCs were isolated from the aorta of wild-type and
zyxin-deﬁcient mice aged 12 weeks. Isolation of cells from
the mouse aorta was performed as described (explant
technique)20 with permission of the Regional Council Kar-
lsruhe and in conformance with the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH publication No. 85-23, revised 1996).
Human arterial smooth muscle cells were isolated from
freshly obtained umbilical cords. The isolation of these cells
was approved by the local Ethics Committee (Heidelberg,
Germany; reference S-182/2013) and was according to the
principles outlined in the Declaration of Helsinki (1997). The
isolated cells were cultured in DMEM supplemented with
50 U/mL penicillin, 50 lg/mL streptomycin, and 15% FBS.
Cells up to passage 3 were used for all experiments. In order
to expose cells to cyclic stretch, they were cultured on
collagen I coated BioFlexTM 6-well plates (Flexcell, Hillsbor-
ough, NC). An FX-5000 Tension System (Flexcell) was used to
subject the cells to 13% cyclic elongation at 0.5 Hz. A cyclic
Table 1. Primers for Quantitative Real-Time PCR Analysis
Gene Primer Sequence (50?30)
Cyclin E2
Forward ACC AGC CAG ACT CTC CGC AA
Reverse CTC CAG ACA GTA CAG GTG GCC A
Fas or CD95
Forward TGG ATC TGG GCT GTC CTG CC
Reverse TTT CAC GAA CCC GCC TCC TCA
ITGA8
Forward TCA AGG CGA GGA ACA GCA A
Reverse CCT TGG GAA CCC GAT GGT
MMP13
Forward CTTCTTCTTGTTGAGCTGGACTC
Reverse CTGTGGAGGTCACTGTAGACT
RGS5
Forward GCGGAGAAGGCAAAGCAA
Reverse GTGGTCAATGTTCACCTCTTTAGG
ITGA8 indicates integrin a8; MMP13, matrix metalloproteinase 13; PCR, polymerase
chain reaction; RGS5, regulator of G-protein signaling 5.
A B
Figure 1. Cyclic stretch induces nuclear translocation of zyxin in
vascular smooth muscle cells (VSMCs). A, Confocal immunoﬂuo-
rescence images of aortic VSMCs from wild-type mice as control
show a punctate distribution of zyxin at focal contact points to the
substrate (indicated by white arrowheads). B, VSMCs exposed to
13% cyclic elongation at 0.5 Hz for 1 hour show a marked
translocation of zyxin from focal adhesions to the nucleus
(indicated by white arrow). Scale bar indicates 50 lm.
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elongation of 18% was used for analyzing the apoptotic
response of the cells to stretch and a 15% elongation was
used for the RhoA activation assay. Intensity and time period
of the stretch stimulus were chosen based on the require-
ments of the assay. Upon application of static stretch, VSMCs
can rearrange their focal contacts, thus escaping the effects
of stretch. To circumvent this, cyclic stretch was applied.
Animal Models
All animal studies were performed with permission of the
Regional Council Karlsruhe and in conformance with the
Guide for the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH publication No. 85-
23, revised 1996). Approximately 24-week-old WT and
zyxin/ mice (n=6 in each group) were prepared for surgical
procedures by anesthesia with isoﬂurane (3% v/v). Deoxycorti-
costerone acetate-salt (DOCA-salt) slow-release pellets (Inno-
vative Research of America, FL; 50 mg) were subsequently
implanted subcutaneously into all mice according to the
manufacturer’s instructions. Drinking water was supplemented
with 1% (w/v) NaCl for up to 21 days following implantation of
the pellets. The resultant increase in blood pressure was
monitored by using a tail-cuff blood pressure measuring
protocol (NIBP, Harvard Apparatus, Panlab, MA), thereby
allowing measurement of both systolic and diastolic blood
pressure. The diastolic pressure was calculated by an algorithm
using the NIBPchart software. The mice were sacriﬁced after
21 days and the excised arteries were ﬁxed using zinc ﬁxative
followed by processing for histological analyses.
A B
C D
Figure 2. Zyxin is a crucial regulator of stretch-sensitive genes in VSMCs. A through C, Volcano plot
analysis of changes in expression of genes in stretched WT and zyxin/ VSMCs (fold expression vs
calculated probability). Cells were stretched at 10% cyclic elongation for 6 hours and compared to
unstretched (static) control cells. Genes that were differentially and signiﬁcantly regulated (P<0.01) are
displayed above the black solid line (n=3 for all experimental groups). 4718 genes were stretch-responsive
in WT compared to only 315 in zyxin/ VSMCs. D, Veriﬁcation of 5 microarray target genes by real-time
RT-PCR, *P<0.05 as indicated, n=3 for all experimental groups. ITGA8 indicates integrin a8; MMP13, matrix
metalloproteinase 13; RGS5, regulator of G-protein signaling 5; RT-PCR, reverse transcriptase polymerase
chain reaction; VSMCs, vascular smooth muscle cells; WT, wild type.
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Perfusion of Isolated Mouse Arteries
Femoral arteries were isolated and perfused as previously
described.20 In brief, the hindlimb was excised and immersed
in perfusion buffer. The femoral artery was separated from
the accompanying vein and connective tissue. Segments of
the femoral artery were cut and mounted onto glass
capillaries with a diameter of 120 lm. The arteries were
perfused using the Pressure Myograph System 110P (Danish
Myo Technology), and the response of the isolated arterial
Table 2. Stretch-Regulated Zyxin-Induced Pathways
No.
Pathway (Source)
Functional Description
Stretch vs Quiescent
P (NES/FDR)
Stretch vs Quiescent/Zyxin Knockout
P (NES/FDR)
1 Central nervous system neuron development (GO pathway) 0.000* (1.95/0.057) 0.900 (0.68/1.000)
2 Muscle contraction (GO pathway) 0.000* (1.94/0.036) 0.394 (1.02/1.000)
3 Muscle system process (GO pathway) 0.000* (1.91/0.045) 0.406 (1.03/1.000)
4 Ear morphogenesis (GO pathway) 0.006* (1.66/0.221) 0.132 (1.24/1.000)
5 Forebrain development (GO pathway) 0.005* (1.64/0.243) 0.308 (1.07/1.000)
6 Regionalization (GO pathway) 0.000* (1.63/0.246) 0.820 (0.85/1.000)
7 Inner ear morphogenesis (GO pathway) 0.008* (1.63/0.242) 0.114 (1.26/1.000)
8 Actin cytoskeleton organization and biogenesis (GO pathway) 0.005* (1.62/0.236) 0.252 (1.11/1.000)
9 Blood vessel morphogenesis (GO pathway) 0.002* (1.62/0.236) 0.252 (1.09/1.000)
10 Embryonic morphogenesis (GO pathway) 0.005* (1.60/0.261) 0.483 (0.99/1.000)
11 Ear development (GO pathway) 0.007* (1.58/0.259) 0.588 (0.93/1.000)
12 Cell maturation (GO pathway) 0.009* (1.57/0.264) 0.725 (0.86/1.000)
13 Di-, tri-valent inorganic cation transport (GO pathway) 0.010* (1.56/0.276) 0.456 (1.00/1.000)
14 Actin filament–based process (GO pathway) 0.003* (1.56/0.275) 0.244 (1.09/1.000)
15 Muscle fiber development (GO pathway) 0.016* (1.55/0.276) 0.505 (0.97/1.000)
16 Angiogenesis (GO pathway) 0.007* (1.54/0.285) 0.290 (1.07/1.000)
17 Anatomical structure formation (GO pathway) 0.005* (1.54/0.283) 0.424 (1.01/1.000)
18 Organ morphogenesis (GO pathway) 0.000* (1.52/0.289) 0.062 (1.18/1.000)
19 Vasculature development (GO pathway) 0.007* (1.51/0.302) 0.279 (1.07/1.000)
20 Blood vessel development (GO pathway) 0.005* (1.51/0.299) 0.273 (1.07/1.000)
21 Embryonic development (GO pathway) 0.000* (1.51/0.290) 0.332 (1.04/1.000)
22 Neurogenesis (GO pathway) 0.002* (1.50/0.285) 0.599 (0.96/1.000)
23 Membrane organization and biogenesis (GO pathway) 0.008* (1.49/0.288) 0.307 (1.05/1.000)
24 Cell–cell adhesion (GO pathway) 0.020* (1.42/0.344) 0.728 (0.91/1.000)
25 Cell morphogenesis (GO pathway) 0.002* (1.42/0.336) 0.761 (0.92/1.000)
26 Cellular structure morphogenesis (GO pathway) 0.001* (1.40/0.355) 0.715 (0.93/1.000)
27 Antigen processing and presentation (KEGG) 0.013* (1.68/0.203) 0.550 (0.95/1.000)
28 Dilated cardiomyopathy (KEGG) 0.004* (1.67/0.187) 0.721 (0.87/1.000)
Selective GSEA-pathway analysis of stretch-sensitive genes in mouse aortic VSMCs (third column) and the role of zyxin therein deduced from changes in gene expression following zyxin
deﬁciency (fourth column). Zyxin-induced pathways that respond in similar fashion in both groups are listed. Quiescent state indicates static VSMCs that were unstretched. All pathways
are derived from the canonical pathway sets provided by KEGG (http://www.genome.jp/kegg/) and GO (pathways molecular function; http://www.geneontology.org). Only pathways
found to be signiﬁcantly altered (P≤0.02) by cyclic stretch and/or zyxin-deﬁciency have been included. As an estimate for the actual grade of enrichment and activation/inhibition of a
given pathway, NES are listed. Additionally, FDR have been included; a value of FDR ≤0.4 is regarded to be signiﬁcant. For analyses with altered parameters, please use the raw data
provided at NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/query) using the sample number [GSE60447] and the link http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=wdorceuih
fapraf&acc=GSE60447. In GSEA, the ranking of genes is with respect to the degree of changes in expression. The normalized enrichment score NES reﬂects the degree to which a
pathway (deﬁned by a set of genes) is overrepresented at the top or bottom of this ranked list of genes for a given comparison (eg, quiescent VSMCs vs stretched VSMCs). Thus, a very
high value for NES (eg, NES >1.8) reﬂects a marked activation of the pathway. Accordingly, a value of, eg, NES <1.6 deﬁnes a signiﬁcant inhibition of the pathway. The false discovery
rate FDR enables estimation of the probability that a pathway deﬁned to be signiﬁcantly regulated by a high NES is falsely positive (eg, FDR=0.4 deﬁnes the probability that 6 of 10
predictions by GSEA are correct). The FDR of 1 means 100% (ie, 100% probability of obtaining the observed sample results when the null hypothesis [tested with ANOVA] is actually true).
FDR indicates false discovery rates; GO, Gene Ontology; GEO, Gene Expression Omnibus; GSEA, Gene Set Enrichment Analysis; KEGG, Kyoto Encyclopedia of Genes and Genomes; NCBI,
National Center for Biotechnology Information; NES, normalized enrichment scores; VSMCs, vascular smooth muscle cells.
*P≤0.02.
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segments to gradually increasing levels of perfusion pressure
was recorded subsequently. Alternatively, perfusion pressure
was gradually increased to 50 mm Hg and appropriate
vasoconstrictor or vasodilator substances were added to
the vessel chamber to induce constriction or dilatation of the
artery as required. The MyoVIEW system and software was
used to record pressure and vessel diameter. All measure-
ments were performed in a blinded fashion with respect to
the genotype of the mice.
Plasmid Construction and Transfection
The zyxin expression plasmid was constructed by subcloning a
full-length polymerase chain reaction (PCR) fragment includ-
ing the ﬁrst stop codon (positions 305 to 1999; NM_011777)
Table 3. Stretch-Regulated Zyxin-Maintained Pathways
No.
Pathway (Source)
Functional Description
Stretch vs Quiescent
P (NES/FDR)
Stretch vs Quiescent/Zyxin
Knockout
P (NES/FDR)
1 Lymphocyte differentiation (GO pathway) 0.553 (0.95/0.824) 0.002* (1.72/0.364)
2 Positive regulation of T-cell activation (GO pathway) 0.560 (0.95/0.828) 0.006* (1.68/0.327)
3 T-cell differentiation (GO pathway) 0.416 (1.02/0.766) 0.002* (1.63/0.385)
4 Epithelial-cell proliferation (GO pathway) 0.318 (1.09/0.699) 0.010* (1.63/0.345)
5 Protein amino acid N-linked glycosylation (GO pathway) 0.434 (1.01/0.777) 0.015* (1.58/0.400)
6 Adaptive immune response (GO pathway) 0.183 (1.19/0.656) 0.012* (1.54/0.372)
7 Adaptive immune response superfamily domains (GO pathway) 0.203 (1.18/0.651) 0.002* (1.54/0.363)
8 Leukocyte differentiation (GO pathway) 0.761 (0.87/0.942) 0.004* (1.51/0.350)
Selective GSEA-pathway analysis of stretch-sensitive genes in mouse aortic VSMCs (third column) and the role of zyxin therein deduced from changes in gene expression following zyxin-
deﬁciency (fourth column). Zyxin-maintained pathways that respond in similar fashion in both groups are shown. Quiescent state indicates static VSMCs that were unstretched. All
pathways are derived from the canonical pathway sets provided by KEGG (http://www.genome.jp/kegg/) and GO (pathways molecular function; http://www.geneontology.org). Only
pathways found to be signiﬁcantly altered (P≤0.02) by cyclic stretch and/or zyxin-deﬁciency have been included. NES are listed. Additionally, FDR have been included; a value of FDR ≤0.4
is regarded to be signiﬁcant. These values are interpreted in the same manner as outlined in the legend to Table 2. Raw data provided at NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/
query) using the sample number [GSE60447]. FDR indicates false discovery rates; GEO, Gene Expression Omnibus; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; KEGG, Kyoto
Encyclopedia of Genes and Genomes; NCBI, National Center for Biotechnology Information; NES, normalized enrichment scores; VSMCs, vascular smooth muscle cells.
*P≤0.02.
Table 4. Stretch-Regulated Zyxin-Repressed Pathways
No.
Pathway (Source)
Functional Description
Stretch vs Quiescent
P (NES/FDR)
Stretch vs Quiescent/Zyxin
Knockout
P (NES/FDR)
1 TGF-b receptor signaling pathway (GO pathway) 0.246 (1.19/0.501) 0.006* (1.68/0.302)
2 Mismatch repair (KEGG) 0.000* (2.12/0.000) 0.375 (1.06/0.961)
3 Homologous recombination (KEGG) 0.002* (1.82/0.056) 0.105 (1.34/0.698)
4 Purine metabolism (KEGG) 0.012* (1.44/0.331) 0.277 (1.09/0.920)
5 DNA repair (GO pathway) 0.000* (1.71/0.106) 0.661 (0.92/1.000)
6 Epithelial-cell differentiation (GO pathway) 0.007* (1.71/0.103) 0.697 (0.86/1.000)
7 DNA recombination (GO pathway) 0.005* (1.70/0.105) 0.381 (1.05/0.917)
8 Reproductive development process (GO pathway) 0.007* (1.69/0.110) 0.577 (0.94/1.000)
9 Covalent chromatin modification (GO pathway) 0.004* (1.67/0.125) 0.954 (0.65/1.000)
10 Response to DNA damage stimulus (GO pathway) 0.005* (1.55/0.239) 0.788 (0.89/1.000)
11 Response to endogenous stimulus (GO pathway) 0.000* (1.51/0.275) 0.980 (0.78/1.000)
Selective GSEA-pathway analysis of stretch-sensitive genes in mouse aortic VSMCs (third column) and the role of zyxin therein deduced from changes in gene expression following zyxin
deﬁciency (fourth column). Zyxin-repressed pathways that respond in similar fashion in both groups are shown. Quiescent state indicates static VSMCs that were unstretched. All pathways
are derived from the canonical pathway sets provided by KEGG (http://www.genome.jp/kegg/) and GO (pathways molecular function; http://www.geneontology.org). Only pathways
found to be signiﬁcantly altered (P≤0.02) by cyclic stretch and/or zyxin-deﬁciency have been included. NES are listed. Additionally, FDR have been included; a value of FDR ≤0.4 is
regarded to be signiﬁcant. These values are interpreted in the same manner as outlined in the legend to Table 2. Raw data provided at NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/
query) using the sample number [GSE60447]. FDR indicates false discovery rates; GEO, Gene Expression Omnibus; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; KEGG, Kyoto
Encyclopedia of Genes and Genomes; NCBI, National Center for Biotechnology Information; NES, normalized enrichment scores; TGF, transforming growth factor; VSMCs, vascular smooth
muscle cells.
*P≤0.02.
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Table 5. Stretch-Regulated Zyxin-Induced Pathways With Opposing Values of NES
No.
Pathway (Source)
Functional Description
Stretch vs Quiescent
P (NES/FDR)
Stretch vs Quiescent/Zyxin
Knockout
P (NES/FDR)
1 Dorsal ventral pattern formation (GO pathway) 0.000* (2.01/0.068) 0.742 (0.83/1.000)
2 Endoderm development (GO pathway) 0.002* (1.96/0.074) 0.739 (0.78/1.000)
3 Cell fate determination (GO pathway) 0.000* (1.95/0.043) 0.602 (0.90/1.000)
4 Axonogenesis (GO pathway) 0.000* (1.86/0.085) 0.035 (1.29/0.610)
5 Neuron morphogenesis during differentiation (GO pathway) 0.000* (1.84/0.106) 0.065 (1.26/0.661)
6 Neurite morphogenesis (GO pathway) 0.000* (1.83/0.101) 0.057 (1.26/0.645)
7 Neuron development (GO pathway) 0.000* (1.83/0.098) 0.117 (1.16/0.771)
8 Extracellular matrix organization and biogenesis (GO pathway) 0.002* (1.83/0.090) 0.195 (1.18/0.756)
9 Neurite development (GO pathway) 0.000* (1.81/0.098) 0.093 (1.20/0.732)
10 Oxygen and reactive oxygen species metabolic process (GO pathway) 0.006* (1.78/0.140) 0.221 (1.19/0.744)
11 Myoblast development (GO pathway) 0.008* (1.78/0.137) 0.786 (0.78/1.000)
12 Extracellular structure organization and biogenesis (GO pathway) 0.002* (1.77/0.136) 0.288 (1.08/0.857)
13 Cellular morphogenesis during differentiation (GO pathway) 0.000* (1.75/0.155) 0.099 (1.19/0.745)
14 Cell fate commitment (GO pathway) 0.002* (1.75/0.156) 0.025 (1.46/0.420)
15 Cell projection morphogenesis (GO pathway) 0.000* (1.74/0.167) 0.427 (1.01/0.982)
16 Myoblast maturation (GO pathway) 0.017* (1.74/0.159) 0.806 (0.78/1.000)
17 Pattern specification process (GO pathway) 0.000* (1.73/0.164) 0.589 (0.96/1.000)
18 Cell part morphogenesis (GO pathway) 0.000* (1.72/0.168) 0.405 (1.01/0.962)
19 Regulation of B-cell activation (GO pathway) 0.006* (1.72/0.162) 0.262 (1.14/0.818)
20 Embryonic skeletal development (GO pathway) 0.012* (1.72/0.159) 0.392 (1.04/0.918)
21 Cell projection organization and biogenesis (GO pathway) 0.000* (1.72/0.158) 0.455 (0.99/0.996)
22 Positive regulation of B-cell activation (GO pathway) 0.008* (1.71/0.155) 0.824 (0.77/1.000)
23 Response to virus (GO pathway) 0.010* (1.71/0.161) 0.072 (1.41/0.430)
24 Axon guidance (GO pathway) 0.005* (1.69/0.176) 0.013* (1.57/0.411)
25 Neuron fate commitment (GO pathway) 0.006* (1.69/0.171) 0.692 (0.85/0.999)
26 Heart development (GO pathway) 0.000* (1.69/0.166) 0.078 (1.21/0.705)
27 Negative regulation of cell differentiation (GO pathway) 0.016* (1.63/0.245) 0.137 (1.22/0.700)
28 Notch signaling pathway (GO pathway) 0.007* (1.63/0.238) 0.728 (0.85/1.000)
29 Circulatory system process (GO pathway) 0.009* (1.63/0.234) 0.067 (1.28/0.613)
30 Response to other organism (GO pathway) 0.012* (1.62/0.240) 0.148 (1.20/0.732)
31 Blood circulation (GO pathway) 0.005* (1.59/0.265) 0.087 (1.27/0.643)
32 Neuron differentiation (GO pathway) 0.000* (1.58/0.266) 0.346 (1.03/0.946)
33 Muscle-cell differentiation (GO pathway) 0.007* (1.58/0.259) 0.083 (1.30/0.602)
34 Negative regulation of developmental process (GO pathway) 0.011* (1.55/0.276) 0.149 (1.18/0.756)
35 Tube morphogenesis (GO pathway) 0.005* (1.54/0.278) 0.020* (1.36/0.535)
36 Small GTPase-mediated signal transduction (GO pathway) 0.003* (1.53/0.288) 0.970 (0.83/1.000)
37 Muscle development (GO pathway) 0.009* (1.53/0.285) 0.363 (1.02/0.945)
38 Negative regulation of cell proliferation (GO pathway) 0.010* (1.52/0.289) 0.697 (0.89/1.000)
39 Taxis (GO pathway) 0.014* (1.51/0.294) 0.006* (1.53/0.361)
40 Innate immune response (GO pathway) 0.020* (1.51/0.292) 0.088 (1.27/0.630)
Continued
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derived from VSMC complementary DNA (cDNA) into the
cDNA 6.2/N-EmGFP TOPO 5.9-kb vector, with the TOPO
cloning reaction used according to the manufacturer’s
recommendations (TOPO Mammalian Expression Vector Kit;
Invitrogen). For the LPP expression plasmid, the same
principle was used with a full-length PCR fragment including
the ﬁrst stop codon (Positions 551 to 2392; NM_178665.5).
Positive constructs were sequenced and used for protein
expression. A suspension of the mouse aortic VSMCs was
transfected batchwise with the zyxin (or LPP)-expressing
construct by using the nucleofection kit (AMAXA) according to
the manufacturer’s instructions. A green ﬂuorescent protein
(GFP)-expressing construct (Lonza) was used as a control for
all transfection experiments. The transgenic expression of
zyxin or LPP was conﬁrmed by immunoﬂuorescence and
Western blot analysis. Cells were used for further experiments
48 hours post--transfection. Primers used for ampliﬁcation of
the zyxin coding sequence were forward 50-GGCC
ATGGCGGCCCCCCGC-30, and reverse 50-TCAGGTCTGGGCTC
TAGCGGAGTG-30; For ampliﬁcation of the LPP coding
sequence, primers used were forward 50-GGCCATGTCTCACC
CATCTTG-30, and reverse 50-CTACAGGTCAGTGCTTGCCT-30.
Transfection With siRNA
VSMCs were transfected with short interfering RNA (siRNA)
directed against MRTF-A as previously described.21 Scram-
bled siRNA (Qiagen) was used as a control. Transfection
with siRNA targeting zyxin was done as previously
described.4 For each well of a 6-well plate, 3 lg of siRNA
was diluted in Opti-MEM I (Invitrogen) using 3 lL of MATra-
si reagent (IBA) giving a ﬁnal volume of 200 lL. After
incubating the mixture for 20 minutes at ambient temper-
ature, the solution was added onto the cells, which had
been pre-incubated in 2 mL Opti-MEM I prior to the
transfection. Cells were then incubated on a magnetic plate
(IBA) at 37°C and 5% CO2. After 20 minutes, cells were
washed and normal cell medium was added to the cells
followed by incubation for 48 hours for knockdown of
MRTF-A.
Gene Expression Analysis
Total RNA was extracted from the mouse aortic VSMCs using
a RNA extraction kit (MachereyNagel) according to the
manufacturers’ instructions. RNA was reverse transcribed to
cDNA using the Moloney murine leukemia virus reverse
transcriptase (M-MLV RT). Quantitative real-time PCR was
performed in a LightCycler 1.2 (Roche) using the SYBR Green–
based method for detection of gene ampliﬁcation according to
the manufacturer’s instructions. Ampliﬁcation of the 60S
ribosomal protein L32 (RPL32) or GAPDH served as an
internal standard. The primer sequences used for ampliﬁca-
tion are listed in Table 1.
Table 5. Continued
No.
Pathway (Source)
Functional Description
Stretch vs Quiescent
P (NES/FDR)
Stretch vs Quiescent/Zyxin
Knockout
P (NES/FDR)
41 Chemotaxis (GO pathway) 0.014* (1.50/0.294) 0.007* (1.53/0.370)
42 Positive regulation of multicellular organismal process (GO pathway) 0.014* (1.50/0.290) 0.011* (1.51/0.348)
43 Generation of neurons (GO pathway) 0.002* (1.50/0.288) 0.484 (0.99/0.993)
44 Regulation of small GTPase-mediated signal transduction (GO pathway) 0.012* (1.50/0.285) 0.442 (0.99/0.994)
45 Behavior (GO pathway) 0.002* (1.48/0.286) 0.369 (1.02/0.943)
46 Skeletal development (GO pathway) 0.012* (1.47/0.293) 0.692 (0.91/1.000)
47 Regulation of signal transduction (GO pathway) 0.000* (1.45/0.319) 0.165 (1.11/0.862)
48 Response to biotic stimulus (GO pathway) 0.016* (1.40/0.357) 0.284 (1.08/0.854)
49 Regulation of multicellular organismal process (GO pathway) 0.017* (1.39/0.362) 0.044 (1.24/0.673)
50 Systemic lupus erythematosus (KEGG) 0.002* (1.72/0.263) 0.100 (1.29/0.715)
51 Endocytosis (KEGG) 0.000* (1.71/0.203) 0.125 (1.17/0.899)
52 Proteasome (KEGG) 0.000* (1.66/0.173) 0.945 (0.66/1.000)
Selective GSEA-pathway analysis of stretch-sensitive genes in mouse aortic VSMCs (third column) and the role of zyxin therein deduced from changes in gene expression following zyxin-
deﬁciency (fourth column). Zyxin-induced pathways that respond in opposite fashion in the 2 groups are shown. Quiescent state indicates static VSMCs that were unstretched. All
pathways are derived from the canonical pathway sets provided by KEGG (http://www.genome.jp/kegg/) and GO (pathways molecular function; http://www.geneontology.org). Only
pathways found to be signiﬁcantly altered (P≤0.02) by cyclic stretch and/or zyxin-deﬁciency have been included. NES are listed. Additionally, FDR have been included; a value of FDR ≤0.4
is regarded to be signiﬁcant. These values are interpreted in the same manner as outlined in the legend to Table 2. Raw data provided at NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/
query) using the sample number [GSE60447]. FDR indicates false discovery rates; GEO, Gene Expression Omnibus; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; KEGG, Kyoto
Encyclopedia of Genes and Genomes; NCBI, National Center for Biotechnology Information; NES, normalized enrichment scores; VSMCs, vascular smooth muscle cells.
*P≤0.02.
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Western Blot Analysis
VSMCs were lysed with sample buffer containing 0.1 lmol/L
DTT and 0.1% of Triton X-100. For preparing cytosolic and
nuclear fractions from cells, separate buffers were prepared.
Samples were separated using SDS-PAGE and blotted onto
polyvinylidene ﬂuoride (PVDF) membranes. Analysis was done
based on a chemiluminescence-based detection system
(ImageQuant LAS 4000 mini). Primary antibodies used were
rabbit anti-zyxin (B71, provided by M. Beckerle, Huntsman
Cancer Institute, Salt Lake City, UT) (1:1000), goat anti-MRTF-
A 1:1000 (Santa Cruz Biotechnology), rabbit anti-tubulin
1:1000 (Cell Signaling), mouse anti-RhoA 1:500 (Cytoskele-
ton), and rabbit anti-LPP 1:1000 (Atlas antibodies).
Nuclear Extraction
The following protocol was used: Mouse aortic VSMCs were
lysed using buffer A containing 10 mmol/L HEPES, 10 mmol/
L KCl, 1 lmol/L EDTA, 1 lmol/L EGTA, 15% Nonidet, and
protease and phosphatase inhibitors. The lysates were
centrifuged (12 000g at 4°C for 15 minutes) and the
supernatant (cytosolic fraction) was transferred to a new
tube and used for Western blot analysis. The residual pellet
containing the nuclear fraction was dissolved in 40 lL buffer
B consisting of 20 mmol/L HEPES, 400 mmol/L NaCl,
0.01 mol/L EDTA, 0.01 mol/L EGTA, 15% Nonidet, and
protease and phosphatase inhibitors. This lysate was soni-
cated 2 times for 5 seconds at 50 W on ice. After centrifu-
gation (12 000g at 4°C for 15 minutes), the supernatant
containing the nuclear fraction was transferred to a new tube
and used for Western blot analysis.
Inhibition of RhoA Activity
Wild-type (WT) and zyxin/ VSMCs were exposed to Rho
Inhibitor I (a C3 transferase denoted hereafter as DRho)
(CT04, Cytoskeleton) at a concentration of 1 lg/mL for 12 or
24 hours, depending on the assay.
RhoA Activation Assay
The RhoA activation assay was performed using a RhoA
activation assay kit (Cytoskeleton) according to the manufac-
turer’s recommendations. Brieﬂy, VSMCs were stretched as
discussed before at 15% cyclic elongation for 15 minutes
following 24 hours of serum starvation. From the total cell
lysates, the active form of RhoA was precipitated using
Table 6. Stretch-Regulated Zyxin-Repressed Pathways With Opposing Values of NES
No.
Pathway (Source)
Functional Description
Stretch vs Quiescent
P (NES/FDR)
Stretch vs Quiescent/Zyxin
Knockout
P (NES/FDR)
1 M phase of mitotic cell cycle (GO pathway) 0.000* (1.92/0.024) 0.000* (2.03/0.020)
2 Mitosis (GO pathway) 0.000* (1.94/0.024) 0.000* (2.01/0.016)
3 M phase (GO pathway) 0.000* (1.96/0.024) 0.000* (1.93/0.037)
4 Chromosome segregation (GO pathway) 0.000* (2.09/0.003) 0.000* (1.92/0.035)
5 Mitotic cell cycle (GO pathway) 0.008* (1.48/0.285) 0.000* (1.87/0.055)
6 Cell cycle phase (GO pathway) 0.000* (1.82/0.048) 0.000* (1.83/0.079)
7 Response to oxidative stress (GO pathway) 0.029 (1.49/0.275) 0.002* (1.77/0.137)
8 Cell division (GO pathway) 0.000* (1.75/0.080) 0.000* (1.74/0.162)
9 Microtubule-based movement (GO pathway) 0.816 (0.81/0.967) 0.002* (1.67/0.297)
10 Sister chromatid segregation (GO pathway) 0.045 (1.59/0.195) 0.006* (1.66/0.300)
11 Mitotic sister chromatid segregation (GO pathway) 0.024 (1.57/0.209) 0.009* (1.65/0.277)
12 Cytoskeleton-dependent intracellular transport (GO pathway) 0.862 (0.79/0.975) 0.002* (1.65/0.265)
13 Cell cycle process (GO pathway) 0.000* (1.46/0.318) 0.000* (1.54/0.476)
14 Starch and sucrose metabolism (KEGG) 0.063 (1.43/0.333) 0.008* (1.78/0.147)
Selective GSEA-pathway analysis of stretch-sensitive genes in mouse aortic VSMCs (third column) and the role of zyxin therein deduced from changes in gene expression following zyxin-
deﬁciency (fourth column). Zyxin-repressed pathways that respond in opposite fashion in the 2 groups are shown. Quiescent state indicates static VSMCs which were unstretched. All
pathways are derived from the canonical pathway sets provided by KEGG (http://www.genome.jp/kegg/) and GO (pathways molecular function; http://www.geneontology.org). Only
pathways found to be signiﬁcantly altered (P≤0.02) by cyclic stretch and/or zyxin-deﬁciency have been included. NES are listed. Additionally, FDR have been included; a value of FDR ≤0.4
is regarded to be signiﬁcant. These values are interpreted in the same manner as outlined in the legend to Table 2. Raw data provided at NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/
query) using the sample number [GSE60447]. FDR indicates false discovery rates; GEO, Gene Expression Omnibus; GO, Gene Ontology; GSEA, Gene Set Enrichment Analysis; KEGG, Kyoto
Encyclopedia of Genes and Genomes; NCBI, National Center for Biotechnology Information; NES, normalized enrichment scores; VSMCs, vascular smooth muscle cells.
*P≤0.02.
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Rhotekin-RBD beads followed by boiling with sample buffer.
The resultant solution was analyzed by SDS-PAGE using the
aforementioned mouse anti-RhoA antibody. A His-tagged
control RhoA protein was used along with a GTPcS-positive
control for each experiment.
Immunoﬂuorescence Analysis
Except for staining stress ﬁbers with Alexa ﬂuor 488-labeled
phalloidin (Invitrogen) and staining for zyxin, where cells were
ﬁxed with 4% paraformaldehyde, in all other cases, cells were
A
J
B
C
D
E
F
G
H
I
Figure 3. Zyxin/ VSMCs proliferate faster than their WT counterparts and are less prone to stretch-
stimulated, FasL-induced apoptosis. A, Statistical summary of proliferation of VSMCs, monitored by counting
the number of cell nuclei stained with DAPI at 0 hour (t0) and after 72 hours (t72). For stretch-stimulated
VSMCs, a 13% cyclic elongation was used. A plasmid encoding GFP was used as a transfection control
(Zyxin/ GFP) for the zyxin/ VSMCs transfected with the zyxin expression construct (Zyxin/Zyx).
*P<0.05, **P<0.01 and ***P<0.001 as indicated, n=5 for all groups except for Zyxin/ GFP t72 and
Zyxin/Zyx t72 where n=3. B through I, Detection of apoptotic nuclei by TUNEL staining (red). DAPI-stained
nuclei are shown in blue. Scale bar represents 100 lm. Cells were stretched at 18% cyclic elongation for
18 hours in the absence or presence of FasL (400 ng/mL). J, Statistical summary of apoptotic TUNEL-positive
nuclei. ***P<0.001 as indicated, n=3 for all groups. DAPI indicates 40,6-diamidino-2-phenylindole; FasL, Fas
ligand; GFP, green ﬂuorescent protein; TUNEL, terminal deoxynucleotidyl transferase–mediated dUTP nick end
labeling; VSMCs, vascular smooth muscle cells; WT, wild type.
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ﬁxed with ice-cold methanol for 15 minutes followed by drying
for 30 minutes. After rehydration, the ﬁxed cells were blocked
with casein solution (0.25% casein, 0.1% BSA, 15 mmol/L
NaN3, 50 mmol/L Tris pH 7.6). Cells were incubated at
ambient temperature with primary antibody for 1 to 2 hours or
overnight at 4°C. In case of arteries, deparafﬁnized vessel
A B
DC
Figure 4. Transient re-expression of zyxin in zyxin/ VSMCs. A, Confocal immunoﬂuorescence image of
VSMCs from wild-type (C57BL/6J) mice showing zyxin localization at focal adhesions (in red). DAPI-stained
nuclei are in blue. B, Absence of zyxin immunoﬂuorescence in zyxin-null VSMCs conﬁrming the speciﬁcity of
the antibody against zyxin. C, Exemplary image of a zyxin-deﬁcient VSMC transfected with a plasmid
expressing the coding sequence for zyxin (Zyxin/ Zyx). Transgenic re-expression occurs at the focal
adhesions, indicating a localization similar to that of the native protein. Scale bar represents 100 lm. D,
Validation of zyxin re-expression by Western blot analysis. DAPI indicates 40,6-diamidino-2-phenylindole;
VSMCs, vascular smooth muscle cells; WT, wild type.
A B
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Figure 5. Zyxin/ VSMCs are primed for migration in a 2D scratch assay. A through H, Representative
images of the migration of WT and zyxin/ VSMCs into a 2D scratch after 24 hours. Scale bar represents
500 lm. The sharpness and contrast of the images were adjusted to the same extent to clearly represent
the migration front. I, Quantitative analysis of migration speed of the cells. The distance traveled by the cell
front was divided by the time period to get the 2D migration speed. **P<0.01, ***P<0.001 as indicated.
For all groups, n=5 except for Zyxin/ GFP and Zyxin/Zyx where n=3. 2D indicates 2-dimensional; GFP,
green ﬂuorescent protein; VSMCs, vascular smooth muscle cells; WT, wild type.
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sections were blocked in a similar manner. Primary antibodies
used were rabbit anti-zyxin (B71) 1:250, rabbit anti-MRTF-A
1:200 (Abcam), mouse anti-LPP 1:200 (Abcam), rabbit anti-
calponin 1:400 (Abcam), and rabbit anti-PCNA 1:200 (Abcam).
After washing, cells were incubated with the secondary
antibody for 1 hour, for an additional 10 minutes with 40,6-
diamidino-2-phenylindole (DAPI) (Invitrogen), and mounted
with Mowiol (Calbiochem). For confocal microscopy analysis, a
IX81 microscope equipped with a IX-DSU disk unit and the
MT20 multi-wavelength illumination system was used in
combination with the cell^R software package (Olympus).
Fluorescence intensity was analyzed using this software by
comparing size-matched areas from 3 to 5 randomly chosen
ﬁelds of view.
2-Dimensional-Cell Migration Assay
Mouse aortic VSMCs (1.59105) were plated in 6-well plastic
plates and grown to conﬂuency in DMEM medium containing
15% FBS. The monolayer was wounded by scratching with a
pipette tip, and the distance between the edges was
measured at 94 magniﬁcation. This was considered as the
starting time point (t=0). After 24 hours (t=24), measure-
ments were made again. Migration velocity was calculated in
micrometers per hour.
3-Dimensional-Collagen Gel Invasion Assay
A modiﬁcation of the spheroid angiogenesis assay22 was
used to measure the invasion of VSMCs into a collagen gel
as previously described.23 Brieﬂy, WT and zyxin/ VSMCs
were seeded (500 cells per spheroid) in growth medium
containing methylcellulose in U-bottom 96-well plates for
24 hours. The spheroids were then suspended into a gel
containing collagen-type-I and the resultant mixture was
allowed to polymerize in 24-well plates. One hundred
microliters of DMEM medium (containing 30% FCS) was
added after 30 minutes over the gel surface. The cumulative
length and number of sprouts originating from individual
spheroids was measured after 24 hours at 910 magniﬁca-
tion. For each genotype, at least 10 spheroids were analyzed
per experiment.
Proliferation Assay
Mouse aortic VSMCs were seeded into 6-well plastic plates
(20 000 cells/well). After 6 hours, cells in a single well were
ﬁxed and stained with DAPI and photographed to determine
the cell number at the starting time point (t=0). The
remaining cells were serum starved for 24 hours. The
medium was replaced by fresh DMEM medium with 15%
FBS, and images were taken in the same manner after
72 hours. A 0% to 13% cyclic elongation was used for the
stretch stimulation where appropriate. The nuclei were
counted using a specially designed algorithm with the help
of ImageJ software. Five images were taken for each well,
and 3 technical replicates were used for each experiment.
For statistical analysis, the ﬁgure “n” represents the number
of biological replicates.
Collagen Gel Compaction Assay
Type I collagen prepared from rat tails was diluted 1:5 with
DMEM. Mouse aortic VSMCs were added to the collagen
solution previously neutralized using 0.1 mol/L NaOH, at a
density of 5000 cells per 0.5 mL in each well of a 48-well
plate. After 2 hours incubation at 37°C, the gels were
gently detached and diameters were measured at 94
magniﬁcation (considered as the starting time point; t=0).
The contraction was monitored after 24 hours. Alternatively,
the medium was replaced with fresh medium containing
endothelin-1, epinephrine, or norepinephrine (each at
100 nmol/L).
Apoptosis Assay
Apoptosis was detected in VSMCs using the in situ cell death
detection kit (Roche) based on TUNEL staining according to
A B
C D
Figure 6. Zyxin-null VSMCs display enhanced invasion in a 3D
collagen gel invasion assay. A and B, Representative images of
sprout formation from 3D spheroids composed of WT and zyxin/
VSMCs, respectively, after 24 hours. Scale bar represents 200 lm.
C and D, Quantitative analysis of cumulative sprout length and
number of sprouts, respectively, as a measure of migration and
invasion of VSMCs into a collagen gel. *P<0.05 as indicated, n=3
for each group. 3D indicates 3-dimensional; VSMCs, vascular
smooth muscle cells; WT, wild type.
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the manufacturer’s instructions. Brieﬂy, cells were seeded
into 6-well BioFlexTM plates. They were serum starved for
24 hours. The serum-free DMEM medium was replaced with
fresh DMEM medium containing 15% FBS followed by
treatment with trimeric Fas ligand (400 ng/mL) (IBA) or
1 lmol/L staurosporine (Tocris Biosciences). Cells were
exposed to 18% cyclic elongation at 0.5 Hz for 18 hours.
This higher intensity of stretch was used to induce more
visible and reproducible apoptosis of the cells. The cells were
ﬁxed and stained with DAPI in combination with the above kit,
and TUNEL-positive nuclei were counted.
Bioinformatic Analysis
Promoter sequences up to 4000 bp upstream of the trans-
lation initiation site of the 5 zyxin-dependent stretch-sensitive
candidate genes (cyclin E2, Fas or CD95, ITGA8, MMP13, and
RGS5) belonging to the species Mus musculus were analyzed
using the MatInspector software (Genomatix). Potential SRF
and PyPu4 consensus sequences in these promoters were
determined in silico. The matrix for the PyPu box is not
incorporated in Genomatix. However, matrices corresponding
to human and murine ETS1 factors and heat shock factors
were found to be similar to the stretch of pyrimidines in the
PyPu box reported earlier.4 Therefore, such matrices were
used to identify similar putative binding sequences closely
resembling the PyPu box.
DNA Microarray Analysis
In order to study the zyxin-dependent regulation of stretch-
sensitive genes, 3 batches of cells each were stretched for
6 hours (0% to 10% cyclic elongation at 0.5 Hz) using aortic
VSMCs from zyxin-null mice (quiescent or stretched) and
A B C
D
Figure 7. Zyxin silencing in human arterial vascular smooth muscle cells (VSMCs) by using short
interfering RNA (siRNA). A through C, Representative immunoﬂuorescence images showing knockdown of
zyxin in human arterial VSMCs 72 hours post-transfection with a siRNA targeting zyxin. Scale bar
represents 100 lm. Scrambled siRNA acts as a control for transfection of cells with a siRNA targeting
zyxin. D, Western blot analysis of zyxin silencing (bottom) and its statistical summary (top), *P<0.05 as
indicated, n=3 for each group.
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aortic VSMCs from wild-type littermates as a control (quies-
cent or stretched). Total RNA was isolated (as mentioned
above) and processed for DNA microarray analysis according
to the manufacturer’s instructions. Gene expression proﬁling
was performed using the GeneChip Mouse Genome 430 2.0
Array from Affymetrix. A custom CDF Version 17 with Entrez-
based gene deﬁnitions was used to annotate the arrays. The
raw ﬂuorescence intensity values were normalized applying
quantile normalization. A commercial software package SAS
JMP10 Genomics, version 6, from SAS was used to analyze
differential gene expression based on ANOVA. A false positive
rate of a=0.05 with false discovery rate correction was taken
as the level of signiﬁcance. The false discovery rate value is
the adjusted P-value, which estimates the probability of
obtaining the observed sampleresults when the null hypoth-
esis is actually true. The probability value ranges between 0
(0%) and 1 (100%). The false discovery rate of 1 means 100%
(ie, 100% probability of obtaining the observed sample results
when the null hypothesis [tested with ANOVA] is actually
true).
Pathway analysis
Gene Set Enrichment Analysis was used to determine whether
deﬁned lists (or sets) of genes exhibit a statistically signiﬁcant
bias in their distribution within a ranked gene list (see http://
www.broadinstitute.org/gsea/ for details).24 Gene Ontology
terms related to molecular function (GO_mf) were used and
pathways belonging to various cell functions were obtained
from public external databases (KEGG, http://www.geno-
me.jp/kegg/). The raw and normalized data are deposited in
the Gene Expression Omnibus database (http://
www.ncbi.nlm.nih.gov/geo/; accession No. GSE60447).
Statistical Analysis
All results are expressed as meansSEM of n individual
experiments. For analyzing differences between 2 individual
experimental groups, an unpaired Student t test was used
with P<0.05 considered statistically signiﬁcant. Differences
among 3 or more experimental groups were analyzed by
1-way ANOVA, followed by a Tukey’s multiple comparison test
A B
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Figure 8. Transient silencing of zyxin by siRNA promotes migration and proliferation of human arterial
VSMCs. A through F, Representative images of the migration of human arterial VSMCs into a 2-D scratch
after 24 hours. Scale bar represents 500 lm. The sharpness and contrast of the images were adjusted to
the same extent to clearly represent the migration front. G, Quantitative analysis of migration speed of the
cells. The distance traveled by the cell front was divided by the time period to get the 2D migration speed.
**P<0.01 as indicated, n=4. H, Statistical summary of proliferation of VSMCs, monitored by counting the
number of cell nuclei stained with DAPI at 0 hour (t0) and after 72 hours (t72). *P<0.05, n=4 for all groups.
2D indicates 2-dimensional; siRNA short interfering RNA; VSMCs, vascular smooth muscle cells.
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for selected pairs of groups with a probability value of P<0.05
considered statistically signiﬁcant.
Results
The Majority of Stretch-Sensitive Genes in VSMCs
Are Zyxin-Dependent
Exposure to (cyclic) stretch causes zyxin translocation from
focal adhesions to the nucleus in both native and cultured
VSMCs5,20 (Figure 1). Since nuclear zyxin is responsible for
regulation of 68% of stretch-sensitive genes in human
endothelial cells,4 we performed a genome-wide DNA micro-
array analysis to test whether zyxin was equally important in
regulating mechanosensitive gene expression in VSMCs.
Approximately 90% of the stretch-sensitive genes in these
cells were regulated by zyxin (Figure 2A through 2C). Five
candidate genes having putative association with at least 1 of
the critical pathways regulating VSMC behavior (ie, prolifer-
ation, migration, contraction, and apoptosis) were validated by
real-time reverse transcriptase polymerase chain reaction (RT-
PCR) (Figure 2D). Expression of all 5 genes (ie, cyclin E2,
tumor necrosis factor receptor superfamily member 6 [Fas or
CD95], integrin a8 [ITGA8], matrix metalloproteinase 13
[MMP13], and regulator of G-protein signaling 5 [RGS5]) was
found to be stretch sensitive and zyxin dependent.
Gene Set Enrichment Analysis (Tables 2 through 6) revealed
that zyxin regulates distinct pathways in response to stretch.Out
of those,we selected 4 based on their importance in determining
the phenotype of VSMCs especially under pathophysiological
conditions. Accordingly, proliferation, apoptosis, migration, and
contractility of zyxin-deﬁcient VSMCs were analyzed in further
detail by in vitro functional assays to determine the signiﬁcance
of the observed changes in gene expression.
Zyxin Negatively Regulates Proliferation and
Sensitizes Stretched VSMCs to Fas Ligand
(FasL)-Induced Apoptosis
Based on the prominent role of 2 validated genes, namely, cyclin
E2 in cell cycle control hence proliferation and the growth-
promoting properties ofMMP13, we compared the proliferation
rate of zyxin-deﬁcient and WT VSMCs. Already without stretch,
zyxin-null VSMCs displayed a markedly increased rate of
proliferation in vitro, which within 72 hours was 1.6-fold
higher as in WT cells (Figure 3A). The capacity of these cells to
proliferate was apparently near maximum, as exposure to cyclic
stretch caused no further increase in proliferation but more
clearly (2.2-fold) exceeded that of the stretched WT VSMCs
(Figure 3A). In fact, stretch led to a decrease in proliferation of
WT VSMCs, which could be due to induction of apoptosis in
these cells. To determine whether this enhanced proliferative
response is strictly zyxin dependent, we tested whether re-
expression of zyxin in the zyxin-null cells (Figure 4) could
normalize proliferation of these cells. Transient re-expression of
zyxin in fact reduced their proliferation rate to that observed
with WT VSMCs while the control plasmid GFP had no
signiﬁcant effect (Figure 3A). It was technically not possible
to re-express zyxin in stretched VSMCs as stretch caused a
signiﬁcant loss of transfected cells.
To test whether the increased expression of the Fas receptor
(Figure 2D) had any effect on apoptosis, we exposed both WT
A
B
Figure 9. Loss of zyxin leads to a contractile deﬁcit of VSMCs
in vitro and isolated femoral arteries in situ. A, Analysis of the ability
of WT and zyxin/ VSMCs to pull a collagen gel, thereby reducing
its diameter over a time period of 24 hours, an indirect measure of
the contractility of the VSMCs. VSMCs seeded in the collagen gels
were additionally stimulated with vasoconstrictor agonists such as
ET1, Eph, and NE (100 nmol/L of each agonist). *P<0.05,
***P<0.001 as indicated, n=4 for each experimental group. B,
Pressure-diameter measurements of isolated femoral arteries from
WT and zyxin/ mice in the absence and presence of increasing
concentrations of vasoconstrictors, Eph and ET1; 108 to
106 mol/L. Acetylcholine was used as a control for vessel
integrity indicated by vasodilatation. *P<0.05, **P<0.01, and
***P<0.001 as indicated, n=3 to 5. Mean values for vessel
diameter from “n” individual experiments were compared between
WT and zyxin/ mice at each data point by unpaired t test. Eph
indicates epinephrine; ET1, endothelin 1; NE, norepinephrine;
VSMCs, vascular smooth muscle cells; WT, wild type.
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and zyxin-null VSMCs to recombinant trimeric FasL in the
presence of cyclic stretch. While FasL had no effect on VSMC
apoptosis in the absence of stretch, stretched zyxin-deﬁcient
VSMCs showed signiﬁcantly less apoptosis in response to FasL
than their WT counterparts as determined by the number of
TUNEL-positive nuclei (Figure 3B through 3J). We were unable
to test the effect of zyxin re-expression in this context because
the transfection process itself (electroporation) induces apop-
tosis and cell death, which precludes a correct interpretation of
FasL-induced apoptosis. Migration often accompanies prolifer-
ation and critically regulates VSMC behavior. We therefore
investigated whether the changes in gene expression and
associated pathways outlined by the DNA microarray analysis
also affected the rate of migration of the VSMCs.
Zyxin-Null Cells Display Enhanced Migration in
Culture
To determine the role of zyxin in cell motility, we used the
scratch-wound assay, which is a 2-dimensional model for
cell migration. After 24 hours, the ability of cells to migrate
to the midline of the scratch was found to be signiﬁcantly
higher in zyxin-null cells (Figure 5A through 5I). Quantitative
analysis revealed a migration speed 1.7-fold higher in
zyxin/ VSMCs as compared to WT VSMCs. Re-expression
of zyxin in zyxin/ VSMCs restored migration speed to
that observed for WT VSMCs, while GFP overexpression had
no effect. VSMCs cultured in a 2-dimensional environment
often behave in a manner different from that in a 3-
dimensional matrix in which they are normally embedded in
the vascular wall. We therefore examined their ability to
invade a collagen gel as a measure of their migratory
potential when seeded in the form of 3-dimensional
spheroids. Spheroids composed of zyxin/ VSMCs consis-
tently showed a higher invasion of the collagen gel
compared to WT VSMCs (Figure 6). Thus, zyxin appears to
negatively regulate cell motility of VSMCs. To verify whether
a transient loss of zyxin in VSMCs was sufﬁcient to induce
an increase in their migration and proliferation, we used a
siRNA targeting zyxin in human arterial VSMCs. Transient
A B
C D
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Figure 10. Zyxin/ stretched VSMCs display a disarray of F-actin stress ﬁbers. A through D, F-actin
stress ﬁbers in control and stretched VSMCs (15% cyclic elongation for 1 hour) were stained with Alexa
ﬂuor 488-labeled phalloidin (white). Scale bar represents 50 lm. E, Quantiﬁcation of F-actin ﬂuorescence
intensity in control and stretched VSMCs with zyxin-deﬁcient VSMCs having prominent F-actin staining
along the edges of the cells (white arrowheads in Figure 10C). **P<0.01, ***P<0.001 as indicated, n=3 for
each group. F, The average number of condensed F-actin deposits (white arrows, D) within the cells was
quantiﬁed. *P<0.05, **P<0.01 and ***P<0.001 as indicated, n.d. indicates not detectable, n=3 for each
group. VSMCs indicates vascular smooth muscle cells; WT, wild type.
DOI: 10.1161/JAHA.114.001712 Journal of the American Heart Association 15
Zyxin and Vascular Smooth Muscle Cell Phenotype Ghosh et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
silencing of zyxin expression led to a signiﬁcant increase in
migration and proliferation (Figure 7 and 8). Apart from a
high rate of proliferation and migration, activated synthetic
VSMCs frequently display a decrease in contractility.
Therefore, we tested whether the zyxin-deﬁcient VSMCs
also have an altered contractility.
Basal and Agonist-Induced Contraction Is
Compromised in Zyxin-Null VSMCs Lacking an
Organized Actin Assembly
A collagen gel compaction assay is an indirect measure of the
ability of cells to contract in vitro, thus leading to a reduction
in gel diameter. Zyxin-deﬁcient VSMCs seeded into a collagen
gel produced a signiﬁcantly lower compaction of the gel after
24 hours as compared to WT VSMCs (Figure 9A). To deter-
mine whether this lack of force generation could be further
unmasked in the presence of a vasoconstrictor, we measured
the gel diameter in the presence of endothelin 1, epinephrine,
and norepinephrine, respectively. The apparent contractile
deﬁcit of the zyxin-deﬁcient VSMCs was in fact further
accentuated by these agonists (Figure 9A). As a direct
method to analyze any contractile deﬁcit of zyxin-null VSMCs,
we pressurized femoral arteries from WT and zyxin/ mice (5
to 12 weeks old) in situ while exposing them to increasing
concentrations of vasoconstrictors such as endothelin 1 and
epinephrine. Femoral arteries from zyxin/ mice displayed a
signiﬁcantly reduced constriction compared to arteries iso-
lated from WT mice (Figure 9B). To assess the origin of this
contractile deﬁcit, we examined stress ﬁber formation in
zyxin-deﬁcient VSMCs both in presence and absence of cyclic
stretch.
Considering data in the literature8 on the role of zyxin
inactin stress ﬁber assembly and repair, we measured the
intensity of actin stress ﬁber labeling with Alexa ﬂuor 488
tagged-phalloidin in WT and zyxin-deﬁcient static and
A B C
D E
Figure 11. Zyxin silencing in human arterial vascular smooth muscle cells (VSMCs) leads to localized
accumulation of F-actin. A through C, Representative immunoﬂuorescence images of human arterial VSMCs
showing F-actin-speciﬁc phalloidin staining. White arrowheads represent accumulation of F-actin-positive
staining at the cell edges and white arrows represent condensed actin spots. Scale bar represents 50 lm.
D, Statistical summary of total F-actin ﬂuorescence intensity, which was not signiﬁcantly different between
groups. E, Quantiﬁcation of condensed F-actin spots (shown by white arrows in C). ***P<0.001 as
indicated, n=3 for each group. n.d. indicates not detectable; siRNA, short interfering RNA.
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stretched VSMCs. Zyxin-null VSMCs showed higher levels of
phalloidin-labeled F-actin already under static conditions
compared to WT VSMCs (Figure 10A, 10C, and 10E). Cyclic
stretch induced a robust increase in stress ﬁber–speciﬁc F-
actin ﬂuorescence in WT as well as in zyxin-deﬁcient VSMCs.
However, of note was the localized accumulation of F-actin
lacking the regular, parallel orientation of stress ﬁbers in WT
VSMCs but being replaced by clusters of condensed F-actin
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Figure 12. Zyxin/ VSMCs have an active RhoA status, which induces stronger nuclear translocation of
MRTF-A in zyxin/ VSMCs. A, Western blot of active RhoA immunoprecipitated from total cell lysates by
Rhotekin Rho binding domain (RBD) beads 15 minutes after exposure of the VSMCs to cyclic stretch (15%
cyclic elongation, 0.5 Hz) or left unstretched. B, Quantiﬁcation of active RhoA: total RhoA ratio as compared
to WT VSMCs. Although stretch induced RhoA activation in both genotypes, RhoA activity was higher in
zyxin/ VSMCs; *P<0.05, **P<0.01, ***P<0.001 as indicated, n=3 for each experimental group. Total
RhoA remained unchanged in WT and zyxin-deﬁcient VSMCs. C, D, F, and G, Representative
immunoﬂuorescence images of MRTF-A (red) localization in WT and zyxin-deﬁcient VSMCs. E and H,
Representative merged images showing MRTF-A and DAPI colocalization in stretched VSMCs (H) but not in
control unstretched VSMCs (E). DAPI-stained nuclei are shown in blue. Scale bar represents 100 lm. I,
Statistical summary of stretch-induced nuclear translocation of MRTF-A in both types of VSMCs. *P<0.05,
**P<0.01, ***P<0.001 as indicated, n=3 for each group. J and K, Western blot analysis (J, representative
Western blot and K, statistical summary) of nuclear and cytosolic fractions from WT and zyxin-deﬁcient
VSMCs demonstrating the stronger nuclear localization of MRTF-A in zyxin-null VSMCs, *P<0.05, **P<0.01
as indicated, n=3 for each group. H-H3 and tubulin were used as markers for the nuclear and cytosolic
fraction, respectively. DAPI indicates 40,6-diamidino-2-phenylindole; H-H3, Histone H3; MRTF-A, myocardin-
related transcription factor A; VSMCs, vascular smooth muscle cells; WT, wild type.
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(Figure 10B, 10D, and 10F). Thus, zyxin-null VSMCs lack an
organized actin network for efﬁcient contraction. These
observations were reproduced in human arterial VSMCs
following transient knockdown of zyxin using siRNA (Figure 7
and 11).
RhoA Is Constitutively Active in Zyxin-Null VSMCs
Triggering Nuclear Accumulation of MRTF-A
Due to the accumulation of phalloidin-labeled F-actin ﬁbers
already in static zyxin-deﬁcient VSMCs along with intense
A B
C D
E
Figure 13. Stronger nuclear translocation of MRTF-A in human
arterial VSMCs following zyxin silencing. A through D, Represen-
tative merged confocal immunoﬂuorescence images of MRTF-A
(red) localization in human arterial VSMCs costained with DAPI
(blue). Scale bar represents 100 lm. White arrowheads indicate
MRTF-A-positive nuclei, while white arrows represent nuclei
negative for MRTF-A. Scrambled siRNA serves as a control for
transfection of cells with siRNA targeting zyxin. E, Statistical
summary of MRTF-A positive nuclei in human arterial VSMCs with
or without zyxin silencing in the presence or absence of cyclic
stretch. *P<0.05, **P<0.01 as indicated, n=3 for each group. DAPI
indicates 40,6-diamidino-2-phenylindole; MRTF-A, myocardin-related
transcription factor A; siRNA, short interfering RNA; VSMCs,
vascular smooth muscle cells.
A
B
Figure 14. MRTF-A silencing by using siRNA
speciﬁc for myocardin-related transcription factor
A (MRTF-A). A, Western blot validation of MRTF-A
silencing by siRNA. Scrambled siRNA acts as a
control for transfection of cells with a siRNA
targeting MRTF-A. Tubulin acts as a loading control.
B, Statistical summary of MRTF-A silencing,
**P<0.01 as indicated, n=3 for each group. siRNA
indicates short interfering RNA.
Figure 15. MRTF-A silencing partially rescues gene expression
changes resulting from zyxin deﬁciency. Effect of MRTF-A silencing
on stretch-sensitive zyxin-dependent gene expression analyzed by
quantitative real-time RT-PCR, *P<0.05 as indicated, n=3 for each
group. ITGA8 indicates integrin a8; MMP13, matrix metalloprotein-
ase 13; MRTF-A, myocardin-related transcription factor A; RGS5,
regulator of G-protein signaling 5; RT-PCR, reverse transcriptase
polymerase chain reaction; siRNA, short interfering RNA.
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F-actin labeling of malformed stress ﬁbers upon stretch, we
examined these cells for activation of the GTPase RhoA, which
is known to be involved in the build-up of such stress ﬁbers.
Following a 15% cyclic elongation of cells for 15 minutes and
pulldown of active RhoA from total cell lysates, signiﬁcantly
higher levels of activated RhoA both in quiescent and
stretched zyxin-deﬁcient VSMCs were observed (Figure 12A
and 12B). VSMCs lacking zyxin thus seem to be in a state
where the GTPase is constantly active.
Signaling via RhoA is a key determinant of MRTF-A activity
by regulating its cellular localization. Hence, we analyzed
whether these cells have an altered subcellular localization of
A
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Figure 16. Inhibition of RhoA activity reduces the proliferation and migration of Zyxin/ VSMCs. A,
Western blot of active RhoA immunoprecipitated from total cell lysates by Rhotekin Rho binding domain
(RBD) beads 12 hours after exposure of the VSMCs to a Rho inhibitor (denoted by DRho) or left untreated.
Serum-starved WT VSMCs were used as a negative control for Rho activation. B, Quantiﬁcation of active
RhoA: total RhoA ratio as compared to WT VSMCs. *P<0.05, **P<0.01 as indicated, n=4 for each
experimental group. Total RhoA remained unchanged in WT and zyxin-deﬁcient VSMCs. C, Statistical
summary of proliferation of VSMCs, monitored by counting the number of cell nuclei stained with DAPI at
0 hour (t0) and after 24 hours (t24). The Rho inhibitor was added at 0 hour and again after 12 hours along
with fresh medium. *P<0.05 as indicated, n=4 for each group. D through K, Representative images of the
migration of WT and zyxin/ VSMCs into a 2-dimensional scratch after 12 hours following treatment with
the Rho inhibitor. Scale bar represents 500 lm. The sharpness and contrast of the images were adjusted to
the same extent to clearly represent the migration front. L, Quantitative analysis of migration speed of the
cells. The distance traveled by the cell front was divided by the time period to get the 2-dimensional
migration speed. *P<0.05, **P<0.01 as indicated, n=4 for each group. DAPI indicates 40,6-diamidino-2-
phenylindole; VSMCs, vascular smooth muscle cells; WT, wild type.
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MRTF-A. Confocal immunoﬂuorescence (Figure 12C through
12I) as well as Western blot analyses of nuclear and cytosolic
fractions (Figure 12J and 12K) derived from quiescent (static
control) and stretched VSMCs revealed a stronger nuclear
localization of MRTF-A already in unstretched zyxin-deﬁcient
VSMCs, which was further accentuated upon short-term
exposure to cyclic stretch. Likewise, in stretched human
arterial VSMCs, there was stronger MRTF-A translocation to
the nucleus upon siRNA-mediated knockdown of zyxin
(Figure 13).
MRTF-A Expression Partly Regulates Zyxin-
Dependent Changes in Gene Expression
Based on the above results, we analyzed whether the zyxin-
dependent changes in stretch-sensitive gene expression in
VSMCs could be associated with the strong MRTF-A
signaling in these cells. To this end, MRTF-A was silenced
in zyxin-null VSMCs using siRNA (Figure 14) and stretch-
induced changes in gene expression of the 5 candidate
genes studied earlier (Figure 2D) were analyzed. Knockdown
of MRTF-A in these cells reversed the changes in 3 out of
the 5 genes found to be mechanosensitive and zyxin-
dependent, namely, cyclin E2, ITGA8, and MMP13 but not
Fas or RGS5 (Figure 15).
RhoA-MRTF-A Axis Drives the Enhanced Migration
and Proliferation of Zyxin/ VSMCs
To test whether RhoA and MRTF-A were causally involved in
the growth-promoting and promigratory phenotype of
zyxin/ VSMCs, we inhibited RhoA activation using a
potent inhibitor of Rho proteins (denoted as DRho). On the
other hand, MRTF-A was transiently silenced using siRNA.
Inhibition of RhoA activation as well as silencing of MRTF-A
signiﬁcantly reduced the migration and proliferation of
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Figure 17. Transient silencing of MRTF-A by siRNA diminishes the migration and proliferation of zyxin/
VSMCs. A through H, Representative images of the migration of WT and zyxin/ VSMCs into a 2-D scratch
after 24 hours. The scratch was made 72 hours post-transfection with siRNA targeting MRTF-A. Scale bar
represents 500 lm. The sharpness and contrast of the images were adjusted to the same extent to clearly
represent the migration front. I, Quantitative analysis of migration speed of the cells. The distance traveled by
the cell front was divided by the time period to get the 2D migration speed. *P<0.05, **P<0.01 and
***P<0.001 as indicated, n=4 for all groups. J, Statistical summary of proliferation of VSMCs, monitored by
counting the number of cell nuclei stained with DAPI at 0 hour (t0) and after 72 hours (t72). **P<0.01, n=4 for
all groups. 2D indicates 2-dimensional; DAPI, 40,6-diamidino-2-phenylindole; MRTF-A, myocardin-related
transcription factor A; siRNA, short interfering RNA; VSMCs, vascular smooth muscle cells; WT, wild type.
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zyxin/ VSMCs, recapitulating those of WT VSMCs (Fig-
ure 16 and 17).
Zyxin-Dependent Stretch-Sensitive Genes Display
Putative SRF Binding Sites
In endothelial cells, zyxin regulates stretch-sensitive gene
expression by binding to a sequence of pyrimidines (PyPu box)
in the proximal promoter region of such genes.4 We therefore
examined the 5 zyxin-dependent candidate genes reported
before for putative PyPu binding sites using an in silico analysis.
We could not identify any reproducible PyPu element in the
promoter regions of these genes (Table 7). Since 3 of these 5
candidate genes were also MRTF-A dependent, we next looked
for SRF binding sites in the promoter sequences of these genes.
Interestingly, all 3 genes, namely, cyclin E2, ITGA8, andMMP13,
were found to contain putative SRF binding sites (Table 8).
Loss of Zyxin Seems Dispensable in Adult Mice in
a Model of Experimental Hypertension
Due to the prominent zyxin-dependency of stretch-
sensitive genes in VSMCs observed in vitro, we examined
the effects of experimentally induced hypertension in
adult mice (24 weeks old) lacking zyxin using a deoxycorti-
costerone acetate (DOCA)-salt model. After 21 days of
treatment with deoxycorticosterone acetate (DOCA)-salt,
systolic and diastolic blood pressure values were simi-
larly elevated in both WT and zyxin/ mice (Figure 18A).
Proliferation of VSMCs as measured by the number of
Table 7. In Silico Promoter Analysis of the 5 Zyxin-Dependent Candidate Genes for Putative PyPu Binding Sites
Gene Matrix Start End C.S M.S Sequence
CyclinE2 V$HSF1.04 663 687 1 0.851 caaagcttctctgggagcTTCTctg
ITGA8 V$HSF1.04 3817 3841 1 0.791 gttgaagcctcaggatccTTCTctc
V$HSF1.04 3522 3546 1 0.761 accccttatgaaggaaacTTCTctc
MMP13 V$HSF1.04 3761 3785 0.85 0.838 tttacatattcttaaaatTTCAatc
RGS5 V$HSF1.04 3577 3601 0.973 0.805 tagagataatctccaaagTTCCatg
V$HSF1.04 2489 2513 1 0.779 tggggtccttcttgttggTTCTatg
V$HSF1.04 1621 1645 1 0.775 tgcaggctgtcctcaaacTTCTgtt
V$HSF1.04 236 260 1 0.789 gggcatgtttctggtggcTTCTgtc
In silico promoter analysis of the 5 zyxin-dependent candidate genes for putative PyPu binding sites. Putative binding sites which remotely resemble the PyPu box are tabulated. The HSF
has some similarity to the PyPu sequence but a prominent and reproducible stretch of pyrimidines was not detectable compared to that observed in ECs.4 A maximum C.S is obtained
when there is a strong match between highly conserved bases of the matrix and the input sequence. A good match to the matrix or the M.S has a value >0.80. Promoter sequences
4000 bp upstream of the transcription start site were analyzed for this purpose. C.S indicates core similarity; ECs, endothelial cells; HSF, heat shock factor; ITGA8, integrin a8; M.S,
matrix similarity; MMP13, matrix metalloproteinase 13; RGS5, regulator of G-protein signaling 5.
Table 8. In Silico Promoter Analysis of the 3 MRTF-A-Regulated Zyxin-Dependent Candidate Genes for Putative SRF Binding Sites
Gene Matrix Start End C.S M.S Sequence
CyclinE2 V$SRF.04 2464 2482 1 0.865 ctaacccgtTATGgcaaga
ITGA8 V$SRF.03 2524 2542 1 0.805 cttcacctatATGGactgc
V$SRF.05 1053 1071 1 0.816 ctagcctgagAAGGctgtg
V$SRF.02 381 399 1 0.868 tgttcCATAtgcggcgaga
V$SRF.04 380 398 1 0.925 ctcgccgcaTATGgaacac
MMP13 V$SRF.04 2915 2933 0.901 0.87 tggaccacaTAAGacccaa
V$SRF.02 1737 1755 1 0.851 gggctCATAtcagggccca
V$SRF.04 1736 1754 1 0.872 gggccctgaTATGagccct
V$SRF.05 1423 1441 1 0.838 ttgacctcaaAAGGgggag
In silico promoter analysis of the 3 MRTF-A-regulated zyxin-dependent candidate genes for putative SRF binding sites. Putative SRF binding sites are tabulated. A maximum C.S is obtained
when there is a strong match between highly conserved bases of the matrix and the input sequence. A good match to the matrix or the M.S has a value >0.80. Promoter sequences
4000 bp upstream of the transcription start site were analyzed for this purpose. C.S indicates core similarity; ITGA8, integrin a8; M.S, matrix similarity; MMP13, matrix metalloproteinase
13; MRTF-A, myocardin-related transcription factor A; SRF, serum response factor.
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PCNA-positive nuclei was not signiﬁcantly different
between the 2 genotypes (Figure 18B through 18D). The
expression of calponin, a component of the cytoskeleton
and contractile apparatus of VSMCs, which is sensitive to
experimental hypertension, was also identical in arterial wall
from both WT and zyxin/ mice (Figure 18E through 18G).
Thus, loss of zyxin seems to be dispensable in mice at
this age.
Isolated Femoral Arteries From Old Zyxin-Null
Mice Are Less Responsive to Changes in
Perfusion Pressure
Isolated femoral arteries from adult (24 weeks) and very old
(72 weeks) WT or zyxin-null mice were perfused at gradually
increasing levels of pressure. No signiﬁcant differences in
A
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Figure 18. Loss of zyxin seems dispensable in mice with exper-
imentally induced hypertension. A, Systolic and diastolic blood
pressure in 6-month-old WT and zyxin-null mice 21 days after
induction of hypertension. Measurements were made by a tail-cuff
method, n=6 for each group. B and C, Representative confocal
immunoﬂuorescence images of femoral artery sections from mice.
Scale bar represents 50 lm. Overlay of PCNA (red) and nuclear
staining with DAPI (blue) is shown in pink. D, Quantitative summary
of PCNA-positive nuclei indicating the number of proliferating
smooth muscle cells in the arterial wall. No signiﬁcant differences
were observed between the 2 groups, n=6 for each group. E and F,
Representative confocal immunoﬂuorescence images of femoral
artery sections from DOCA-salt-treated WT and zyxin-null mice
showing the expression of calponin (red). Scale bar represents
50 lm. G, Statistical summary of calponin intensity in femoral artery
sections from DOCA-treated mice. Values were not signiﬁcantly
different between the 2 groups, n=6 for each group. DAPI indicates
40,6-diamidino-2-phenylindole; DOCA, deoxycorticosterone acetate;
PCNA, proliferating cell nuclear antigen; WT, wild type.
A
B
Figure 19. Femoral arteries from old zyxin-null mice are less
sensitive to changes in vessel diameter with increasing levels of
perfusion pressure. A, Pressure-diameter readings in femoral
arteries from 24-week-old wild-type (WT) and zyxin-null mice.
Values were not signiﬁcantly different between the 2 groups, n=5
for each group. B, Changes in vessel diameter in femoral arteries
from 72-week-old WT and zyxin-null mice exposed to gradually
increasing levels of perfusion pressure. *P<0.05, n=5 for femoral
arteries from WT mice and n=3 for femoral arteries from zyxin-null
mice. Differences in mean vessel diameter between the 2 groups at
each data point were analyzed by an unpaired t test.
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response to elevated levels of perfusion pressure—so-called
myogenic response—were observed in arteries from adult WT
and zyxin-null mice (Figure 19A). Arteries from very old
zyxin/ mice, however, failed to show signiﬁcant changes in
diameter at higher values of perfusion pressure (Figure 19B).
Since the zyxin/ VSMCs showed an activated phenotype
in vitro that was not replicated in adult zyxin-null mice both
under in vivo and in situ conditions, we hypothesized that
redundant members of the zyxin family might be responsible
for masking the cardiovascular phenotype in mice until they
are much older (ie, 18 months as compared to 6 months).
The LIM Domain Protein LPP Likely Compensates
for Loss of Zyxin in VSMCs
Owing to the lack of a cardiovascular phenotype in zyxin/
mice at baseline conditions, we tested the possibility of the
closely related member of the zyxin family, namely LPP, as a
likely source of functional compensation. LPP was found to be
expressed in VSMCs and colocalized with zyxin at focal
adhesions (Figure 20). As a proof of principle, we transiently
overexpressed LPP protein in zyxin/ VSMCs and measured
their migration and proliferation. Overexpression of LPP was
conﬁrmed by both immunoﬂuorescence and Western blot
analysis (Figure 21). A 1.8-fold increase in LPP expression
was sufﬁcient to reduce both proliferation and migration of
zyxin/ VSMCs to the level of WT VSMCs (Figure 22).
Discussion
Among the focal adhesion proteins, zyxin has been studied in
some detail, and several lines of evidence suggest that it may
function as a mechanosensor.4,5,20 With substantial evidence
of the importance of zyxin in endothelial cells,4,20 we aimed at
deﬁning its role in VSMCs. This study reports a different
subset of stretch-induced genes regulated by zyxin in VSMCs
compared to that observed for endothelial cells. We used an
in vitro approach with primary VSMCs from these animals to
study the consequences of a permanent loss of zyxin at the
cellular level. We assume that 1 reason for the apparent lack
of a (cardio)vascular phenotype in zyxin-deﬁcient mice (up to
18 months old; data not shown) under baseline conditions is
functional redundancy of the closely related zyxin family
members LPP and thyroid hormone receptor interactor 6.
Interestingly, LPP-deﬁcient mice also do not have a distinct
phenotype,25 despite the presence of a more severe pheno-
type in ﬂies and zebraﬁsh lacking zyxin and LPP, respec-
tively.26,27
Using pathway analysis tools, zyxin-dependent genes could
be attributed to important pathways mediating VSMC behav-
ior. These pathways (Tables 2 through 6) indicate that in
VSMCs, zyxin is pro-apoptotic and inhibits proliferation and
migration, which was replicated in our in vitro experiments.
Previously, conﬂicting roles of zyxin in apoptosis have been
reported with zyxin promoting apoptosis28 or inhibiting it.29
This may be due to the cell type–speciﬁc function of zyxin
and/or the type and relative potency of the stimulus used to
induce apoptosis.
The reduced collagen gel compaction of zyxin-null VSMCs
might be indicative for generating insufﬁcient force to pull on
the collagen ﬁbers. The poor response to vasoconstrictors
could be due to higher expression of RGS5 (Figure 2D), which
is known to limit G-protein coupled receptor–mediated
contraction of VSMCs. Although we found stronger F-actin
staining in zyxin-deﬁcient VSMCs, this was mainly localized
along the cell boundary or in condensed actin-rich regions,
and thus may explain the lack of tension exerted by these
cells on the collagen matrix. Zyxin-null ﬁbroblasts are known
to have a defect in building robust stress ﬁbers.30,31 Zyxin-
deﬁcient VSMCs seem to differ in some aspects. While there
is a defect in building robust stress ﬁbers, F-actin staining is
more intense but concentrated along the cell boundary or
spotlike within the cytoplasm. Thus, zyxin-null VSMCs try to
A
B C D
Figure 20. LPP protein colocalizes with zyxin at focal adhesions
in VSMCs. A, Representative merged confocal immunoﬂuorescence
image of an aortic VSMC from wild-type mice showing a punctate
distribution of zyxin and LPP at focal contact points to the substrate
(indicated by white arrowheads). Colocalization is indicated in
yellow. B through D, Individual confocal immunoﬂuorescence
images of VSMC nucleus, LPP and zyxin expression, respectively,
shown in blue, green, and red. Scale bar indicates 50 lm. DAPI
indicates 40,6-diamidino-2-phenylindole; LPP, lipoma preferred
partner; VSMCs, vascular smooth muscle cells.
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accumulate actin in response to stretch but fail to build robust
stress ﬁbers, so that actin aggregates form as reported
previously.31 Another difference between this study and the
previous report30 might be due to the use of mouse
embryonic ﬁbroblasts as compared to aortic VSMCs from
adult mice in which dynamic stress ﬁbers might have had
more time to adapt to the lack of zyxin. Finally, the
composition of stress ﬁbers could also differ between VSMCs
and ﬁbroblasts since this is known to depend on factors such
as the inherent motility of cells.32
Since RhoA is associated with cell contractility,33 the
increased RhoA activity in poorly contractile zyxin-null VSMCs
seems counterintuitive. However, without strings of parallel
stress ﬁbers, the increased RhoA activity in the zyxin-deﬁcient
VSMCs could not generate sufﬁcient tension. Interestingly,
despite their enhanced RhoA activity, zyxin-null VSMCs
displayed an increased migratory capacity as compared to
WT VSMCs. This, however, is not unprecedented. There is
evidence that RhoA regulates membrane protrusion with high
RhoA activity localized to cell protrusions and retracting tails
of randomly migrating cells.34 Moreover, there are reports of
RhoA supporting migration of VSMCs35 and thereby their
involvement in vascular remodeling processes such as
neointima formation and arteriogenesis.36 Indeed, we
observed an impaired migration and proliferation of zyxin/
VSMCs upon inhibition of RhoA activation.
Rho GTPases can regulate the activity of MRTF-A and B,
which are co-activators of the transcription factor SRF.
Accordingly, the strong enrichment of MRTF-A in the nucleus
of zyxin-null VSMCs paralleled the increased RhoA activity.
Although there is substantial evidence for MRTF-A support-
ing the differentiated (contractile) state of VSMCs through
promoting expression of speciﬁc SRF target genes, recent
evidence suggests that a high level of MRTF-A activity may
actually drive VSMC migration and proliferation under
pathophysiological conditions where myocardin is downreg-
ulated.15 Expression of myocardin is decreased in most
vascular remodeling processes and also in dedifferentiated
VSMCs in culture. Likewise, in stretch-stimulated VSMCs,
myocardin is exported out of the nucleus16 while MRTF-A
translocates to the nucleus. Thus, the increase in nuclear
MRTF-A seems to switch the SRF-dependent gene program
from phenotype stabilization toward migration and prolifer-
ation. Accordingly, transient silencing of MRTF-A in zyxin/
A B C
D
Figure 21. Transient overexpression of LPP in zyxin/ VSMCs. A, Confocal immunoﬂuorescence image
of VSMCs from zyxin/ mice showing LPP localization at focal adhesions (in red). B, Zyxin/ VSMCs
transfected with GFP as a transfection control. C, Exemplary image of zyxin-deﬁcient VSMCs transfected
with a plasmid expressing the coding sequence for LPP (Zyxin/ LPP). Scale bar represents 100 lm. D,
Validation of LPP over-expression by Western blot analysis showing a 1.8-fold increase in LPP expression,
n=4 for each group. GFP indicates green ﬂuorescent protein; LPP, lipoma preferred partner; VSMCs,
vascular smooth muscle cells.
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VSMCs signiﬁcantly reduced their migration and prolifera-
tion. In dedifferentiated VSMCs, modulation of SRF activity
by MRTF-A via Rho signaling in fact has a signiﬁcant impact
on proliferation and migration.15,21 In certain cancer cell
lines,21 constitutive MRTF-A activity is critical for their
motility and invasiveness. In this context, decreased levels of
zyxin have been associated with several forms of can-
cers.9,37 It is thus likely that the absence of zyxin in VSMCs
triggers a promigratory and activated phenotype by a
corresponding shift toward the RhoA-MRTF-A axis, which
drives basal SRF activity. We could rescue part of zyxin-
dependent gene expression in zyxin-deﬁcient VSMCs by
knockdown of MRTF-A (Figure 15). Thus, zyxin does seem to
partly regulate gene expression through the MRTF-A-SRF
pathway. We have previously reported the binding of zyxin to
a sequence of pyrimidines (PyPu box) in the promoter
regions of stretch-sensitive zyxin-dependent genes in endo-
thelial cells.4 However, in silico analysis of putative PyPu
binding sites in the promoter regions of candidate mechano-
sensitive genes in VSMCs did not reveal such a consensus
sequence (Table 7). This together with the much higher
threshold of stretch-dependent activation of zyxin in
VSMCs20 indicates that the zyxin-dependent gene expression
likely follows a different mechanism in VSMCs compared to
endothelial cells. Interestingly, in agreement with the partial
regulation of zyxin-dependent gene expression by MRTF-A,
several putative SRF binding sites were observed in the
promoter regions of zyxin-dependent mechanosensitive can-
didate genes (Table 8). Therefore, the RhoA-MRTF-A axis
seems to be at least 1 of the mechanisms regulating zyxin-
dependent gene expression in VSMCs.
Despite the presence of a pronounced in vitro phenotype in
zyxin-null VSMCs, adult mice lacking zyxin did not display
changes in blood pressure or arterial remodeling in compar-
ison to WT mice when challenged with experimental hyper-
tension. Accordingly, isolated femoral arteries from adult
A B
C D
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Figure 22. Overexpression of LPP in zyxin/ VSMCs recapitulates the migration and proliferation
behavior of WT VSMCs. A through H, Representative images of the migration of WT and zyxin/ VSMCs
into a 2D scratch after 24 hours. Scale bar represents 500 lm. The sharpness and contrast of the images
were adjusted to the same extent to clearly represent the migration front. I, Quantitative analysis of
migration speed of the cells. The distance traveled by the cell front was divided by the time period to get the
2D migration speed. *P<0.05, **P<0.01 as indicated. For all groups, n=4. J, Statistical summary of
proliferation of VSMCs, monitored by counting the number of cell nuclei stained with DAPI at 0 hour (t0)
and after 72 hours (t72). A plasmid encoding GFP was used as a transfection control (Zyxin/ GFP) for the
zyxin/ VSMCs transfected with the LPP expression construct (Zyxin/ LPP). **P<0.01 as indicated,
n=4 for all groups. 2D indicates 2-dimensional; DAPI, 40,6-diamidino-2-phenylindole; GFP, green ﬂuorescent
protein; LPP, lipoma preferred partner; VSMCs, vascular smooth muscle cells; WT, wild type.
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zyxin-null mice were identical to those from WT mice in their
(myogenic) response to increasing levels of perfusion
pressure in situ. Interestingly, in very old zyxin-null mice,
there was a stark deﬁcit in this so-called myogenic response,
suggesting that in the arterial vessel wall of these mice either
the contractile capacity of the VSMCs was downregulated or
their communication with the extracellular matrix was
disturbed.
The important role of zyxin in regulating the VSMC
phenotype at the cellular level might have been masked in
animal studies. Our preliminary studies in very old hyperten-
sive (deoxycorticosterone acetate or DOCA-salt-treated) zy-
xin/ mice in fact point to an in vivo phenotype (data not
shown) closely resembling our observations with cultured
zyxin/ VSMCs. Further extensive in vivo studies with zyxin-
deﬁcient mice that are challenged with pathophysiological
stress and knockdown of multiple zyxin family members in
mice should further elucidate the varied vascular functions of
this mechanotransducer protein.
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